Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells

Gene Ther. 2000 Feb;7(3):241-8. doi: 10.1038/sj.gt.3301065.

Abstract

HER-2/neu is overexpressed in 25-30% of human breast cancers. We prepared an anti-HER-2/neu hammerhead ribozyme expressed by a recombinant adenovirus (rAdHER-Rz). Human breast cancer cell lines were transduced with high efficiency, resulting in decreased HER-2/neu expression. In vivo injections of rAdHER-Rz into BT-474 tumors established in nude mice inhibited tumor growth to 20% of mock-treated controls. Similar in vivo effects were shown in MCF-7 cells, which do not overexpress HER-2/neu. The growth inhibitory effects of rAdHER-Rz were greater than those of an antisense-expressing vector. These results suggest the utility of anti-HER-2/neu ribozymes as a rational strategy for gene therapy of breast cancer. Gene Therapy (2000) 7, 241-248.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenoviridae / genetics*
  • Animals
  • Base Sequence
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy*
  • Cell Division
  • Gene Targeting / methods*
  • Genes, erbB-2 / genetics*
  • Humans
  • Mice
  • Mice, Nude
  • Molecular Sequence Data
  • Polymerase Chain Reaction / methods
  • RNA, Catalytic / genetics
  • Tumor Cells, Cultured

Substances

  • RNA, Catalytic
  • Rz967